Research programme: prostate cancer therapy - Lynx/UroGene

Drug Profile

Research programme: prostate cancer therapy - Lynx/UroGene

Alternative Names: Prostate cancer therapy research programme - Lynx/UroGene

Latest Information Update: 16 Sep 2004

Price : $50

At a glance

  • Originator Lynx Therapeutics; UroGene
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 16 Sep 2004 Discontinued - Preclinical for Prostate cancer in France (unspecified route)
  • 16 Sep 2004 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 27 Mar 2001 Preclinical development for Prostate cancer in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top